Advertisement
New Zealand markets closed

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NZD/USD

    0.5953
    +0.0003 (+0.05%)
     

  • NZD/EUR

    0.5555
    +0.0015 (+0.27%)
     

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • OIL

    84.26
    +0.69 (+0.83%)
     

  • GOLD

    2,357.60
    +15.10 (+0.64%)
     

  • NASDAQ

    17,539.41
    +108.91 (+0.62%)
     

  • FTSE

    8,119.20
    +40.34 (+0.50%)
     

  • Dow Jones

    38,087.65
    +1.85 (+0.00%)
     

  • DAX

    18,080.82
    +163.54 (+0.91%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • NZD/JPY

    93.3240
    +0.8280 (+0.90%)
     

Ventas (VTR) Q2 FFO and Revenues Beat Estimates

Zacks Equity Research
Updated

Have you been eager to see how Ventas, Inc. VTR performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this Chicago, IL-based healthcare real estate investment trust (REIT) earnings release this morning:

A FFO Beat

Ventas came out with normalized funds from operations (FFO) per share of $1.08, beating the Zacks Consensus Estimate of $1.02.

Higher revenues were primarily responsible for this FFO beat.

How Was the Earnings Surprise Trend?

Ventas has a mixed surprise history. Before posting a FFO beat in Q2, the company delivered positive surprises in one of the trailing four quarters, met in other two and missed in another, resulting in an average negative surprise of 1.00%. This is depicted in the graph below:

Ventas, Inc. Price and EPS Surprise
 

Ventas, Inc. Price and EPS Surprise | Ventas, Inc. Quote

ADVERTISEMENT

Revenues Came In Higher Than Expected

Ventas posted revenues of $942.3 million, which beat the Zacks Consensus Estimate of $918.7 million. Further, it compared favorably with the year-ago number of $895.5 million.

Key Developments to Note

Ventas improved its 2018 normalized FFO per share outlook and expects it in the range of $4.02-$4.07. The company expects same-store cash net operating income growth to be 0.75-1.5% in 2018.

What Zacks Rank Says

Ventas has a Zacks Rank #3 (Hold). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change.

(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)

Check back later for our full write up on this VTR earnings report!

Note: Anything related to earnings presented in this write-up represent funds from operations (FFO) — a widely used metric to gauge the performance of REITs.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Ventas, Inc. (VTR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.